11 results about "Passive Immunotherapy" patented technology

The present invention relates to an immunogenic polysaccharide-protein conjugate comprising a capsular polysaccharide (CP) from Streptococcus agalactiae (commonly known as group B streptococcus (GBS)) and a carrier protein, wherein the CP is selected from the group consisting of serotypes Ia, Ib, II, III, IV, V, VI, VII, VIII, and IX, and wherein the sialic acid level of the CP is higher than about 60%. The present invention also relates to methods of making the conjugate and immunogenic compositions comprising the conjugate. The present invention also relates to an immunogenic composition comprising a polysaccharide-protein conjugate, wherein the conjugate comprises CP from GBS serotype IV and at least one additional serotype. The present invention further relates to methods of using the compositions disclosed herein to induce an immune response against GBS in a subject and / or to reduce or prevent invasive GBS disease in a subject. The antibodies generated can be used for the treatment or prevention of GBS infection by passive immunotherapy.

The invention discloses a hybridoma cell strain capable of secreting a monoclonal antibody with bovine coronavirus neutralizing activity and application of the hybridoma cell strain, and belongs to the technical field of antibody drugs. The preservation number of the hybridoma cell strain is CCTCC (China Center For Type Culture Collection) NO: C2025147. The hybridoma cell strain can be used for preparing a monoclonal antibody with bovine coronavirus neutralizing activity, and the monoclonal antibody shows excellent neutralizing titer on bovine coronavirus and is subjected to cross-neutralization reaction with related sheep coronavirus (cpCoV). The monoclonal antibody obtained by the invention not only can be used for developing a high-sensitivity specific diagnostic reagent aiming at the BCoV, but also provides a new core biological material for developing a passive immunotherapy preparation with a potential broad-spectrum protection effect; the method has important application value in the aspects of coping with virus variation and improving the overall prevention and control capability of the coronavirus of the ruminant.

The present invention relates to monoclonal antibodies which have high anti-RSV neutralizing titers. The invention further provides for isolated nucleic acids encoding the antibodies of the invention and host cells transformed therewith. The invention yet further provides for diagnostic, prophylactic and therapeutic methods employing the antibodies and nucleic acids of the invention, particularly as a passive immunotherapy agent in infants and the elderly.

Provided are a broad-spectrum coronavirus-neutralizing antibody and a use thereof. The antibody CYFN1006-1 comprises a heavy chain variable region VH and a light chain variable region VL, wherein the VH comprises CDRH1 to CDRH3 having amino acid sequences as shown in SEQ ID NOs: 1-3; and the VL comprises CDRL1 to CDRL3 having amino acid sequences as shown in SEQ ID NOs: 4-6. CYFN1006-1 is a broad-spectrum highly-efficient coronavirus-neutralizing antibody, can efficiently neutralize all currently circulating SARS-CoV-2 variants, shows medium efficacy on SARS-CoV, and provides a new choice for solving the problems of viral escape and drug resistance encountered in the application of monoclonal antibody passive immunotherapy against novel coronavirus infection.

The invention relates to the field of passive immunotherapies for the prophylaxis and treatment of poisonings caused intentionally or accidentally by ingestion or inhalation of ricin, a toxin from the castor oil plant Ricinus communis. The present invention relates more specifically to an antibody having a high affinity for the A chain of ricin and which allows in vitro neutralization of the toxin as well as short- and long-term protection against this poisoning. The present invention also relates to a murine / human chimeric antibody and a humanized antibody for the prevention or treatment of ricin poisoning.

The invention relates to immunogenic compositions comprising a capsular polysaccharide (CP) from Streptococcus agalactiae, commonly referred to as group B streptococcus (GBS), conjugated to a carrier protein, and optionally including an aluminum-based adjuvant. The invention further relates to methods for inducing an immune response in subjects against GBS and / or for reducing or preventing invasive GBS disease in subjects using the compositions disclosed herein. The resulting antibodies can be used to treat or prevent GBS infection via passive immunotherapy.

The present invention relates to monoclonal antibodies which have high anti-RSV neutralizing titers. The invention further provides for isolated nucleic acids encoding the antibodies of the invention and host cells transformed therewith. The invention yet further provides for diagnostic, prophylactic and therapeutic methods employing the antibodies and nucleic acids of the invention, particularly as a passive immunotherapy agent in infants and the elderly.

The invention relates to immunogenic compositions comprising a capsular polysaccharide (CP) from Streptococcus agalactiae, commonly referred to as group B Streptococcus (GBS), conjugated to a carrier protein, and optionally including an aluminum-based adjuvant. The invention further relates to methods for inducing an immune response in subjects against GBS and / or for reducing or preventing invasive GBS disease in subjects using the compositions disclosed herein. The resulting antibodies can be used to treat or prevent GBS infection via passive immunotherapy.

The invention lies in the field of passive immunotherapies for the prophylaxis and treatment of poisoning caused intentionally or accidentally by swallowing, injection or inhalation of ricin, which is a toxin derived from the Ricinus communis castor oil plant. The present invention specifically relates to an antibody with a high affinity for the ricin A chain and which enables in vitro neutralization of the toxin and also short- and long-term protection against said poisoning. The present invention also relates to a murine / human chimeric antibody and a humanized antibody for preventing or treating ricin poisoning.

The application discloses a Mycoplasma bovum LP586 protein, a polyclonal antibody thereof and application. The amino acid sequence of the LP586 protein is shown as SEQ ID NO. 1, the LP586 protein has high conservation, is positioned on the cell membrane surface of the Mycoplasma bovum, and has multiple biological functions such as specific adhesion to EBL cells, combination with extracellular matrix molecules and activation of plasminogen in the presence of tPA. The application further provides a high-titer specific polyclonal antibody prepared by immunization. The LP586 protein can be used as a key antigen for preparing a Mycoplasma bovum subunit vaccine, a diagnostic reagent or a therapeutic drug; and the polyclonal antibody thereof can be used for preparing a diagnostic reagent or a passive immunotherapy preparation. The application provides a brand-new high-efficiency target and product development basis for prevention and control of the Mycoplasma bovum disease.

The invention lies in the field of passive immunotherapies for the prophylaxis and treatment of poisoning caused intentionally or accidentally by swallowing, injection or inhalation of ricin, which is a toxin derived from the Ricinus communis castor oil plant. The present invention specifically relates to an antibody with a high affinity for the ricin A chain and which enables in vitro neutralization of the toxin and also short- and long-term protection against said poisoning. The present invention also relates to a murine / human chimeric antibody and a humanized antibody for preventing or treating ricin poisoning.